A high-dose bortezomib neuropathy with sensory ataxia and myelin involvement.
- FILOSTO M
- ROSSI G
- PELIZZARI AM
- BUZIO S
- TENTORIO M
- BROGLIO L
- MANCUSO M
- RINALDI M
- SCARPELLI M
- A. PADOVANI
Publication date
January 2007
DOI Publisher
Elsevier BV:PO Box 211, 1000 AE Amsterdam Netherlands:011 31 20 4853757, 011 31 20 4853642, 011 31 20 4853641, EMAIL: nlinfo-f@elsevier.nl, INTERNET: http://www.elsevier.nl, Fax: 011 31 20 4853598 ISSN
0022-510X Citation count (estimate)
6Abstract
Bortezomib, a proteasome inhibitor used in the treatment of multiple myeloma, is known to induce an axonal, dose-dependent neuropathy clinically characterized by pain, paresthesias, burning dysesthesias and numbness. In this study, we describe a patient treated with high-dose bortezomib whose main clinical feature was severe sensory ataxia. Electrodiagnostic studies showed, other than axonal changes, myelin involvement
Add to ORKG